Bio-Path Holdings

BELLAIRE, TX · Biotechnology · 9 employees

Bio-Path is a biotechnology company developing targeted therapies for acute myeloid leukemia (AML), lymphoma, chronic lymphocytic leukemia, gynecological cancer and other challenging cancers. The company’s lead product candidate, prexigebersen (Liposomal Grb2 Antisense), formerly BP1001, is currently being assessed in a Phase 2 clinical study in previously untreated AML patients, who are not eligi

Funding history

Series seed — $4.0M — Oct 2024
Series seed — $4.0M — Jun 2024
Series seed — $1.3M — Apr 2024
Series seed — $318K — Apr 2024

Recent signals

Oct 22, 2025: SEC 8-K (5.02): On October 22, 2025, Bio-Path Holdings, Inc. appointed Vikram Grover as President, Chief Executive Officer, Chief Financial Officer, and a member of the Board of Directors, marking a significant change in management. This appointment coincided with the resignation of Douglas Morris as Interim Chief Executive Officer and Interim Chief Financial Officer, although he retains his position as a Board member. Additionally, the resignation of Paul Aubert from the Board of Directors was accepted on the same day. These leadership changes are expected to influence the company's strategic direction and operational effectiveness going forward.
Jan 10, 2025: Launched Bio-Path Holdings Announces 2025 Clinical Development and Operational Updates Focused on Cancer and Obesity Treatments.
Oct 22, 2024: Raised $4.0M in Series seed
Oct 09, 2024: Bio-Path Holdings Announces $4.0 Million Private Placement Partnership with H.C. Wainwright & Co.
Jun 13, 2024: Raised $4.0M in Series seed
Apr 26, 2024: Raised $1.3M in Series seed
Apr 05, 2024: Raised $318K in Series seed

See plans & pricing → Track Bio-Path Holdings’s funding, hiring, and signals — with verified contacts — on Fundz.